Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. OBJECTIVE: To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patients with early breast cancer. DESIGN, SETTING, A...

全面介紹

Na minha lista:
書目詳細資料
發表在:JAMA Oncol
Main Authors: Friedl, Thomas W. P., Fehm, Tanja, Müller, Volkmar, Lichtenegger, Werner, Blohmer, Jens, Lorenz, Ralf, Forstbauer, Helmut, Fink, Visnja, Bekes, Inga, Huober, Jens, Jückstock, Julia, Schneeweiss, Andreas, Tesch, Hans, Mahner, Sven, Brucker, Sara Y., Heinrich, Georg, Häberle, Lothar, Fasching, Peter A., Beckmann, Matthias W., Coleman, Robert E., Janni, Wolfgang, Rack, Brigitte
格式: Artigo
語言:Inglês
出版: American Medical Association 2021
主題:
Original Investigation
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227465/
https://ncbi.nlm.nih.gov/pubmed/34165508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.1854
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍